CYRAMZA Injection
Ramucirumab
10 mg/ml
ELI LILLY & CO LTD.
| Pack size | 1 Vial (10 ml) |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 2402.60 AED |
Available as:
Indications
CYRAMZA Injection is used for:
For use in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Ramucirumab :
Mechanism of Action
Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells.
Note
CYRAMZA 10 mg/ml Injection manufactured by ELI LILLY & CO LTD.. Its generic name is Ramucirumab. CYRAMZA is availble in Saudi Arabia.
Farmaco SA drug index information on CYRAMZA Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.